Miguel A Pagan, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: Ciudad Primavera, 1003 Calle Bogota, Cidra, PR 00739 Phone: 787-360-7873 |
20/20 Optical,jeira Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: Calle Jose De Diego, 30, Cidra, PR 00739 Phone: 787-714-4550 Fax: 787-714-4550 |
Pearle Vision Plaza Cidra Mall Optometrist Medicare: Not Enrolled in Medicare Practice Location: Carr #172 - Esq. Carr # 787, Plaza Cidra Mall Local # 22, Cidra, PR 00739 Phone: 787-434-0004 Fax: 787-739-2480 |
Enid D Aramburu, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Carr#172 Esq. 787 Local 22, Cidra, PR 00739 Phone: 787-434-0004 |
William Velez Ramos, O.D. Optometrist - Corneal and Contact Management Medicare: Medicare Enrolled Practice Location: Carr. 734 Km 0.6 Bo. Arenas, Cidra, PR 00739 Phone: 787-714-2520 |
Dr. Angel Francisco Romero, O.D. Optometrist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 14 Calle Padilla El Caribe, Cidra, PR 00739 Phone: 787-667-7185 |
Luis A De Jesus Miranda, DO Optometrist Medicare: Not Enrolled in Medicare Practice Location: Calle Jose De Diego #30, Cidra, PR 00739 Phone: 787-714-4550 Fax: 787-714-4550 |
News Archive
In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns
Researchers have identified a metabolic enzyme and pathway in some triple-negative breast cancer (TNBC) patients, which they hope could serve as a biomarker to select patients to receive targeted therapy.
A Florida businessman filed suit today against Atkins Nutritionals, Inc., and the Estate of Dr. Robert C. Atkins, claiming that the late diet author's controversial high-fat, low-carbohydrate regimen caused severe heart disease, necessitating angioplasty and a stent. He is seeking a court injunction banning Atkins Nutritionals from marketing its products without a warning of potential health risks and asks for compensatory damages.
Celera Corporation and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries.
ADial Pharmaceuticals, LLC, announced today that the U.S. Food and Drug Administration has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder in certain targeted genotypes population only.
› Verified 2 days ago